Synthesis of new N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives and evaluation of their AChE, BChE, and BACE-1 inhibitory activities

dc.authorid0000-0002-8651-826X
dc.authorid0009-0002-1614-2380
dc.authorid0000-0003-4038-8823
dc.contributor.authorTutus, Beyzanur
dc.contributor.authorKaya, Aybuke Zuleyha
dc.contributor.authorBaz, Yonca
dc.contributor.authorEvren, Asaf Evrim
dc.contributor.authorOzkan, Beguem Nurpelin Saglik
dc.contributor.authorYurttas, Leyla
dc.date.accessioned2025-05-20T19:00:04Z
dc.date.issued2024
dc.departmentBilecik Şeyh Edebali Üniversitesi
dc.description.abstractIn this study, the synthesis of N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives (3a-3k) and to investigate their acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and beta-secretase 1 (BACE-1) inhibition activity were aimed. Mass, H-1 NMR, and C-13 NMR spectra were utilized to determine the structure of the synthesized compounds. Compounds 3b, 3c, 3f, and 3j showed AChE inhibitory activity which compound 3c (IC50 = 0.030 +/- 0.001 mu M) showed AChE inhibitory activity as high as the reference drug donepezil (IC50 = 0.0201 +/- 0.0010 mu M). Conversely, none of the compounds showed BChE activity. Compounds 3c and 3j showed the highest BACE-1 inhibitory activity and IC50 value was found as 0.119 +/- 0.004 mu M for compound 3j whereas IC50 value was 0.110 +/- 0.005 mu M for donepezil, which is one of the reference substance. Molecular docking studies have been carried out using the data retrieved from the server of the Protein Data Bank (PDBID: 4EY7 and 2ZJM). Using in silico approach behavior active compounds (3c and 3j) and their binding modes clarified.
dc.identifier.doi10.1002/ddr.22214
dc.identifier.issn0272-4391
dc.identifier.issn1098-2299
dc.identifier.issue4
dc.identifier.pmid38816986
dc.identifier.scopus2-s2.0-85195013789
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/ddr.22214
dc.identifier.urihttps://hdl.handle.net/11552/8784
dc.identifier.volume85
dc.identifier.wosWOS:001235816600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWoS
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakWoS - Science Citation Index Expanded
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofDrug Development Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250518
dc.subjectAlzheimer Disease (AD)
dc.subjectBenzothiazole
dc.subjectCholinesterase Inhibitors
dc.subjectBeta-Secretase (BACE-1)
dc.titleSynthesis of new N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives and evaluation of their AChE, BChE, and BACE-1 inhibitory activities
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Makale.pdf
Boyut:
5.35 MB
Biçim:
Adobe Portable Document Format